Product/Composition:- | Febuxostat tablets |
---|---|
Strength:- | 40 mg, 80 mg |
Form:- | Oral Tablets |
Reference Brands:- | Uloric(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Febuxostat inhibits xanthine oxidase, reducing uric acid production. It effectively lowers serum uric acid levels, preventing gout attacks and urate crystal formation. Benefits include improved uricemia management, decreased gout flare frequency, and enhanced quality of life with a favorable safety profile when used appropriately.
Febuxostat tablets are approved in the EU and US for managing hyperuricemia and gout. In the EU, brands like Uloric (by Takeda) are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and quality. In the US, FDA approval relies on extensive clinical data and biosimilarity evaluations. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory dossiers, compliance, and registration, visit PharmaTradz. We support efficient market access for febuxostat tablets, ensuring adherence to European and American standards, helping you navigate complex regulatory landscapes seamlessly for safe, effective gout management.